Saloner Brendan, Heller Daliah, Davis Corey S, Sherman Susan G
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA; email:
Drug Use Initiatives, Vital Strategies, New York, NY, USA.
Annu Rev Public Health. 2025 Apr;46(1):369-387. doi: 10.1146/annurev-publhealth-071723-112620. Epub 2024 Dec 17.
Harm reduction programs provide tools that enable people who use drugs to do so more safely in a nonstigmatizing environment without the goal of them necessarily seeking treatment or abstinence. Most harm reduction programs in the United States distribute sterile syringes and naloxone and safely dispose of used syringes and other drug use supplies. Many also provide drug checking services, and other safer use supplies. These programs exist on a limited scale and often face restrictions on their funding and scope of operations. While research demonstrates the effectiveness of existing programs in preventing infectious disease transmission and fatal overdose, there is less evidence about conditions that support the effective expansion and sustainment of existing models. Other harm reduction interventions such as overdose prevention centers and safer supply programs have promising international evidence but are prohibited or severely restricted under US law. In this review, we summarize the evidence for harm reduction interventions, describe the policy environment in which they exist, and provide recommendations to better align drug policy with existing and emerging evidence in the US context.
减少伤害项目提供各种工具,使吸毒者能够在无歧视的环境中更安全地吸毒,而不一定以寻求治疗或戒毒为目标。美国的大多数减少伤害项目分发无菌注射器和纳洛酮,并安全处理用过的注射器及其他吸毒用品。许多项目还提供毒品检测服务和其他更安全的使用用品。这些项目规模有限,且在资金和运营范围方面常常面临限制。虽然研究表明现有项目在预防传染病传播和致命过量用药方面有效,但关于支持现有模式有效扩展和持续开展的条件的证据较少。其他减少伤害干预措施,如过量用药预防中心和更安全供应项目,在国际上有很有前景的证据,但在美国法律下被禁止或受到严格限制。在本综述中,我们总结减少伤害干预措施的证据,描述其所处的政策环境,并提出建议,以便在美国背景下使毒品政策更好地与现有及新出现的证据保持一致。